Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Lags Revenue Estimates
Portfolio Pulse from
Caribou Biosciences, Inc. (CRBU) reported a Q4 loss of $0.39 per share, slightly better than the Zacks Consensus Estimate of a $0.40 loss. However, the company lagged in revenue estimates.
March 10, 2025 | 10:30 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Caribou Biosciences reported a Q4 loss of $0.39 per share, slightly better than expected, but missed revenue estimates. This could lead to a neutral to slightly negative short-term impact on the stock price.
The earnings per share (EPS) was slightly better than expected, which is a positive sign. However, missing revenue estimates is a negative factor. The combination of these factors suggests a neutral to slightly negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100